1. Home
  2. CISS vs ENSC Comparison

CISS vs ENSC Comparison

Compare CISS & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3is Inc.

CISS

C3is Inc.

HOLD

Current Price

$2.08

Market Cap

1.9M

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$0.25

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISS
ENSC
Founded
2022
2003
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
1.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
CISS
ENSC
Price
$2.08
$0.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.3M
887.9K
Earning Date
05-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$55.01
Revenue Next Year
N/A
$1,033.97
P/E Ratio
$0.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.08
$0.23
52 Week High
$6.06
$2.75

Technical Indicators

Market Signals
Indicator
CISS
ENSC
Relative Strength Index (RSI) 43.18 37.26
Support Level $2.00 $0.23
Resistance Level $2.23 $0.32
Average True Range (ATR) 0.23 0.03
MACD -0.05 0.00
Stochastic Oscillator 38.82 23.00

Price Performance

Historical Comparison
CISS
ENSC

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: